QUOTE AND NEWS
DailyFinance  Sep 29  Comment 
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the...
DailyFinance  Sep 26  Comment 
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in...
Benzinga  Sep 26  Comment 
AVEO Oncology (NASDAQ: AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company's headquarters in Cambridge, Massachusetts,...
SeekingAlpha  Sep 14  Comment 
By Saul Markman: [Originally published 9/1/2014] AVEO Oncology (NASDAQ:AVEO) is a Cambridge Mass. based company, founded 10 years ago and traded on NASDAQ. AVEO has created new and interesting oncology treatments, mostly antibodies. An...
DailyFinance  May 31  Comment 
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended...
SeekingAlpha  May 1  Comment 
ByPropThink: By David Phillips In February, AVEO Pharmaceuticals (AVEO) announced that Japanese drug maker Astellas Pharma (OTCPK:ALPMY) terminated its three-year collaboration for tivozanib, putting to bed the long-troubled, oral VEGF receptor...
Benzinga  Apr 7  Comment 
Pier 1 Imports (NYSE: PIR) shares fell 1.49% to touch a new 52-week low of $17.88. Pier 1 shares have dropped 19.87% over the past 52 weeks, while the S&P 500 index has gained 20.07% in the same period. NeuStar (NYSE: NSR) shares dropped 1.31%...
StreetInsider.com  Mar 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AVEO+Oncology+%28AVEO%29+Regains+Rights+to+AV-203+from+Biogen+%28BIIB%29/9303263.html for the full story.
SeekingAlpha  Mar 14  Comment 
AVEO Pharmaceuticals (AVEO) Q4 2013 Earnings Call March 13, 2014 4:30 pm ET Executives Robert Kloppenburg - Vice President of Corporate Communications and Public Affairs Tuan Ha-Ngoc - Chief Executive Officer, President, Principal...
DailyFinance  Mar 13  Comment 
AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance. “With the cost-containment measures implemented in the second half of 2013, AVEO ended...




 

AVEO Pharmaceuticals (AVEO) (NASDAQ:AVEO) is a pharmaceutical drug company that specializes on cancer treatments. It has a cancer treatment product, tivozanib, in Phase 3 of the FDA approval process. It also is in collaboration with Merck for a cancer treatment product AV-299, which helps determine cancer biology in patients. This product is in Phase 2. [1]

Along with other pharmaceutical companies, government regulation and the FDA approval process decides whether a pharmaceutical company's drug can enter the commercial market. AVEO is dependent on its cancer treatment product, tivozanib, to pass Phase 3 and enter the commercial market, otherwise it decreases future earnings as the company either scraps the product or reinvest and restart the process. Since it already passed Phase 2, it is expected to have a positive outcome for Phase 3. [1]

The company's initial public offering of stock traded on the NASDAQ exchange on 11 March 2010. The proposed offer price range was $13-$15 and traded below the low end at $9. The company offered 9 million shares and raised $81 million. [1]

At the year end 31 December 2009, the company had $20.72 million in total revenue, up 5.4% from $19.66 million in total revenue in 2008. The company reported a net loss of $44.2 million, down from a net loss of $32.47 million. [1]

References

  1. 1.0 1.1 1.2 1.3 AVEO Pharmaceuticals S-1/A
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki